Back to top
more

Adaptimmune Therapeutics (ADAP)

(Real Time Quote from BATS)

$1.02 USD

1.02
463,972

-0.02 (-1.92%)

Updated May 29, 2024 11:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines

Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.

    What's in Store for Johnson Controls (JCI) in Q4 Earnings?

    Johnson Controls (JCI) expects to post strong earnings on integration and productivity savings and cost benefits from mergers.

      Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

      Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.

        AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook

        AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.

          Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3

          Epizyme (EPZM) posted narrower-than-expected loss in the third quarter of 2017. It plans to meet the FDA to begin the registration strategy for its lead pipeline candidate, tazemetostat, in the next quarter.

            Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales

            Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.

              Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y

              Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.

                Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat

                Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.

                  Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View

                  Alkermes' (ALKS) earnings beat estimates but sales lagged the same in the third quarter of 2017.

                    Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Down Y/Y

                    Bayer AG's (BAYRY) core earnings per share from continuing operations beat expectations in the third quarter of 2017 and the company lost de facto control over the Covestro Group at the end of the quarter.

                      Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up

                      Alexion Pharmaceuticals, Inc.???s (ALXN) beat earnings estimates but missed sales estimates in the third quarter of 2017.

                        Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View

                        Vertex Pharma (VRTX) third-quarter earnings increased from the year-ago period led by strong sales of CF drugs.

                          Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised

                          Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.

                            Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics

                            AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.

                              Impax Laboratories and Amneal Pharmaceuticals Agree to Merge

                              Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.

                                Immune Design's Sarcoma Candidate to Enter Phase III in 2018

                                Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.

                                  The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene

                                  The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene

                                    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

                                    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

                                      Bayer to Sell Select Business Lines to Close Monsanto Buyout

                                      Bayer Aktiengesellschaft (BAYRY) inked a deal to sell selected Crop Science businesses to BASF for EUR 5.9 billion to as a part of its strategy to complete the planned acquisition of Monsanto Co.

                                        Shire's New Formulation of Oncaspar Gets CHMP Recommendation

                                        Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.

                                          AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge

                                          AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.

                                            Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up

                                            Flexion Therapeutics (FLXN) announced that its non-opioid intra-articular injection for treating knee pain has received FDA approval.

                                              ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status

                                              ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.

                                                Surging Earnings Estimates Signal Good News for Adaptimmune Therapeutics (ADAP)

                                                Adaptimmune Therapeutics (ADAP) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

                                                  Zacks.com featured highlights: Adaptimmune Therapeutics, Barnes Group, Mobile TeleSystems, JA Solar Holdings and Newtek Business Services

                                                  Zacks.com featured highlights: Adaptimmune Therapeutics, Barnes Group, Mobile TeleSystems, JA Solar Holdings and Newtek Business Services